Professor’s privilege is a legal default: the individual researcher, not the university, owns the patent rights to their own inventions. Sweden is the clearest surviving large-scale example of it in Europe — but the legal rule by itself does not explain how Swedish universities actually move research into products and companies. This guide covers the operational side: how three of Sweden’s most research-intensive universities — KTH Royal Institute of Technology, Chalmers University of Technology, and Karolinska Institutet — have built commercialization support around a rule that gives their technology transfer offices (TTOs) no automatic claim on anything.
The legal starting point: lärarundantaget
Sweden’s professor’s privilege is known domestically as lärarundantaget, the “teacher’s exemption.” It carves university teaching and research staff out of Sweden’s general employee-invention statute, the Act on the Right to Employees’ Inventions (1949:345), which otherwise lets an employer claim rights to inventions made in the course of employment. Patentable inventions made by an employed teacher in the course of their duties fall outside that Act — ownership starts with the inventor, not the institution, and it applies to Sweden’s other research universities as well, not only the three profiled here (see, for example, the Swedish University of Agricultural Sciences’ own explanation of the teachers’ exemption). For the general legal mechanics — how professor’s privilege compares to Bayh-Dole-style institutional ownership, and where the rule still applies internationally — see CASRAI’s Professor’s Privilege dictionary entry; this guide picks up where that entry leaves off, at the level of what a Swedish TTO can and cannot do as a result.
What lärarundantaget forces every Swedish TTO to be
Because a Swedish university has no default ownership claim, none of KTH, Chalmers, or Karolinska Institutet operates a conventional Bayh-Dole-style invention-disclosure-and-title-election process, the way a U.S. research university does under the Bayh-Dole Act. A researcher who wants nothing to do with the university’s support structure is legally free to patent, license, or found a company entirely independently. In practice, all three universities have converted that structural weakness into a service relationship: the TTO’s job is to make itself worth voluntarily involving, offering patent-cost funding, prior-art searching, licensing introductions, and startup formation support — in exchange for a negotiated stake (equity, a license, or a service fee) rather than a default entitlement. The three institutions have arrived at three visibly different organizational answers to that same constraint.
KTH: a two-tier advisory-office-plus-holding-company model
KTH runs a deliberately split structure. KTH Innovation is the university’s own free advisory service, open to current students, researchers, and employees. Its stated role is to be contacted early — before publication or public disclosure creates prior art that blocks patenting — and from there it offers patentability investigations, help filing patent applications, funding toward patent costs, drafting of confidentiality and shareholder agreements, and support taking a license or a trademark to market. Because of lärarundantaget, none of this requires the researcher to sign anything over to KTH first; it is support offered to whoever chooses to use it.
Separately, KTH Holding AB is the university’s wholly owned holding company, which sits above a set of venture-investment vehicles rather than running commercialization services directly. It helped establish KTH Chalmers Capital — formed in 2006 as a joint early-stage investment vehicle between KTH and Chalmers, aimed at commercially promising technology connected to either university — alongside other funds such as STING Capital and Luminar Ventures. That two-tier design keeps the free, advisory relationship (KTH Innovation) structurally separate from the equity-taking, investment relationship (KTH Holding AB and its funds): a researcher can use one without automatically triggering the other.
Chalmers Ventures: incubator and investor combined under one roof
Chalmers takes a more integrated approach. Chalmers Ventures describes itself as the deep-tech investor inside the Chalmers entrepreneurial ecosystem, explicitly combining venture creation and investment “under the same roof” rather than splitting advisory support from equity investment the way KTH does. Its process runs through five stages — identifying research and technology ideas, shaping and starting a company around one, validating the business model, scaling it, and eventually exiting — and the organization states it maintains active ownership involvement across that whole arc, from idea through to exit, with returns reinvested back into new research and innovation. The practical effect for a Chalmers researcher is the same starting condition as at KTH (nothing is owed to the university by default under lärarundantaget), but a single organization, rather than two, is where that researcher goes for both early advisory support and any later capital.
KI Innovation: a life-science-specific ecosystem at Karolinska Institutet
Karolinska Institutet, Sweden’s dedicated medical university, channels commercialization through KI Innovation (formerly branded Karolinska Innovations AB), which is organized around the specific shape of life-science translation rather than general deep-tech commercialization. It combines an early-stage advisory service (the Innovation Lab, which helps a researcher assess feasibility and choose between forming a company or pursuing a collaboration), a startup-scaling incubator (KI Incubator), a shared community and lab space connecting academia, startups, and industry (KI Science Park), and co-investment capability for portfolio companies. As with KTH and Chalmers, engagement is the researcher’s choice under lärarundantaget rather than an institutional entitlement — but the life-sciences focus shapes what KI Innovation actually specializes in: regulatory pathway awareness, clinical translation, and the longer, more capital-intensive runway typical of biomedical spinouts, compared to the general engineering and deep-tech orientation at KTH and Chalmers.
Comparing the three models
| Institution | Structure | Advisory vs. investment split | Sector focus |
|---|---|---|---|
| KTH | KTH Innovation (advisory office) + KTH Holding AB (holding company over investment funds, incl. KTH Chalmers Capital) | Split into two distinct entities | General engineering / deep tech |
| Chalmers | Chalmers Ventures (integrated incubator and venture investor) | Combined in a single organization | Deep tech, university spinouts |
| Karolinska Institutet | KI Innovation (Innovation Lab, KI Incubator, KI Science Park, co-investment) | Multiple functions under one umbrella brand | Life sciences / biomedical |
None of the three publishes a standard, publicly posted equity or royalty percentage for what a researcher gives up in exchange for support — unlike a Bayh-Dole institution’s disclosure-and-title process, where the institution’s rights are fixed by policy before negotiation begins, terms in a professor’s-privilege system are negotiated case by case, because the starting allocation of rights is different in the first place. A research administrator advising a Swedish-affiliated inventor should treat any specific equity or licensing figure as something to confirm directly with the relevant office, not something a general guide can state as a fixed rule.
Why this matters for cross-border collaboration
The practical stakes show up most clearly in joint funding arrangements. A collaborative grant that pairs a Swedish co-investigator with a U.S. institution operating under Bayh-Dole is combining two structurally opposite starting points: on the U.S. side, the employing institution has the first right to elect title to a federally funded invention (subject to disclosure obligations and the government’s retained march-in rights); on the Swedish side, the individual researcher owns the invention outright unless they have separately agreed otherwise. A single, uniform invention-rights clause written for one side’s default will not automatically fit the other. Research administrators structuring a joint award, subaward, or collaboration agreement involving a Swedish co-investigator should confirm IP ownership and assignment terms explicitly in the collaboration agreement itself, rather than assuming either country’s institutional default applies globally within the project.
How Sweden compares to other professor’s-privilege-adjacent systems
Sweden is not the only country CASRAI has profiled where the operational tech-transfer model diverges sharply from the U.S. institutional-ownership norm. Israel’s system — built around university-affiliated, for-profit commercialization companies such as Yissum, Yeda, and Ramot — starts from institutional ownership rather than individual privilege, but arrives at a similarly distinct organizational answer to “who actually runs commercialization.” See CASRAI’s guide to Israel’s tech transfer model for that comparison, alongside guides to the UK’s technology transfer model, Canada’s university tech transfer model, and France’s SATT network.
Frequently asked questions
Does lärarundantaget mean Swedish universities have no rights to research results at all?
No. It means the university has no automatic rights to a patentable invention by default. Universities can and do acquire rights — through a researcher’s voluntary assignment, through a negotiated agreement with KTH Innovation, Chalmers Ventures, or KI Innovation, or through a specific employment or sponsored-research contract that displaces the default rule for a particular project.
Does lärarundantaget cover PhD students as well as professors?
KTH’s own guidance states its support is available to current students as well as researchers and employees, and describes the exemption as applying to both PhD students and professors in its plain-language explanation — though the precise legal boundary of who counts as covered depends on the specific statute and employment relationship, and should be confirmed against the underlying 1949:345 Act rather than assumed from general practice.
Is lärarundantaget under threat of being abolished, like it was in Germany, Denmark, Finland, and Norway?
Sweden has, at various points, seen policy discussion about moving toward institutional ownership, and CASRAI’s general Professor’s Privilege entry notes Sweden as the clearest still-live example among major European systems specifically because most comparable countries have already abolished the rule. Any specific reform proposal or timeline should be verified directly against current Swedish government and Riksdag sources rather than assumed static, since this is exactly the kind of national policy detail that can change.
Do KTH Innovation, Chalmers Ventures, and KI Innovation only work with faculty inventors?
No. All three explicitly extend support to students as well as research staff — reflecting the same lärarundantaget default, which is not limited to tenured professors, but to research and teaching staff (and, per university guidance, students) whose inventions would otherwise fall under the general employee-invention rule.
This guide covers how Sweden’s professor’s privilege operates in practice through university-affiliated commercialization structures. For the underlying legal concept and how it compares internationally, see CASRAI’s Professor’s Privilege dictionary entry. For the broader technology transfer landscape, see the Technology Transfer pillar page.
